AVEREL: A Randomised Phase 111 Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER-2Positive Locally Recurrent/Metastatic Breast Cancer

Bibliographic Details
Main Authors: Gianni, L., Romieu, G., Lichinister, M., Serrano, S., Mansutti, M., Pivot, X., Mariani, P., Andre, F., Chan, Arlene, Lipatov, O., Chan, S., Wardley, A., Greil, R., Moore, N., Prot, S., Pallaud, C., Semiglazov, V.
Format: Journal Article
Published: American Society of Clinical Oncology 2013
Online Access:http://hdl.handle.net/20.500.11937/4315
_version_ 1848744481400029184
author Gianni, L.
Romieu, G.
Lichinister, M.
Serrano, S.
Mansutti, M.
Pivot, X.
Mariani, P.
Andre, F.
Chan, Arlene
Lipatov, O.
Chan, S.
Wardley, A.
Greil, R.
Moore, N.
Prot, S.
Pallaud, C.
Semiglazov, V.
author_facet Gianni, L.
Romieu, G.
Lichinister, M.
Serrano, S.
Mansutti, M.
Pivot, X.
Mariani, P.
Andre, F.
Chan, Arlene
Lipatov, O.
Chan, S.
Wardley, A.
Greil, R.
Moore, N.
Prot, S.
Pallaud, C.
Semiglazov, V.
author_sort Gianni, L.
building Curtin Institutional Repository
collection Online Access
first_indexed 2025-11-14T06:02:09Z
format Journal Article
id curtin-20.500.11937-4315
institution Curtin University Malaysia
institution_category Local University
last_indexed 2025-11-14T06:02:09Z
publishDate 2013
publisher American Society of Clinical Oncology
recordtype eprints
repository_type Digital Repository
spelling curtin-20.500.11937-43152018-12-14T00:46:04Z AVEREL: A Randomised Phase 111 Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER-2Positive Locally Recurrent/Metastatic Breast Cancer Gianni, L. Romieu, G. Lichinister, M. Serrano, S. Mansutti, M. Pivot, X. Mariani, P. Andre, F. Chan, Arlene Lipatov, O. Chan, S. Wardley, A. Greil, R. Moore, N. Prot, S. Pallaud, C. Semiglazov, V. 2013 Journal Article http://hdl.handle.net/20.500.11937/4315 American Society of Clinical Oncology restricted
spellingShingle Gianni, L.
Romieu, G.
Lichinister, M.
Serrano, S.
Mansutti, M.
Pivot, X.
Mariani, P.
Andre, F.
Chan, Arlene
Lipatov, O.
Chan, S.
Wardley, A.
Greil, R.
Moore, N.
Prot, S.
Pallaud, C.
Semiglazov, V.
AVEREL: A Randomised Phase 111 Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER-2Positive Locally Recurrent/Metastatic Breast Cancer
title AVEREL: A Randomised Phase 111 Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER-2Positive Locally Recurrent/Metastatic Breast Cancer
title_full AVEREL: A Randomised Phase 111 Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER-2Positive Locally Recurrent/Metastatic Breast Cancer
title_fullStr AVEREL: A Randomised Phase 111 Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER-2Positive Locally Recurrent/Metastatic Breast Cancer
title_full_unstemmed AVEREL: A Randomised Phase 111 Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER-2Positive Locally Recurrent/Metastatic Breast Cancer
title_short AVEREL: A Randomised Phase 111 Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER-2Positive Locally Recurrent/Metastatic Breast Cancer
title_sort averel: a randomised phase 111 trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for her-2positive locally recurrent/metastatic breast cancer
url http://hdl.handle.net/20.500.11937/4315